Equillium

Equillium Inc is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory disorders that have significant unmet medical needs. The company's leading product candidate, EQ001, is a first-in-class monoclonal antibody that specifically targets the immune checkpoint receptor CD6, which is crucial in regulating effector T cell activity associated with various immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, an antibody targeting the CD6-ALCAM pathway, which is undergoing Phase 3 trials for acute graft-versus-host disease and Phase 1b trials for lupus nephritis. The company is also advancing EQ101, a cytokine inhibitor aimed at IL-2, IL-9, and IL-15, which is poised to enter Phase 2 studies for alopecia areata, and EQ102, another cytokine inhibitor that targets IL-15 and IL-21, which is ready for clinical development.

Bruce D. Steel

Co-Founder, Director and President and CEO

1 past transactions

Bioniz Therapeutics

Acquisition in 2022
Bioniz Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative peptide therapeutics aimed at treating immune diseases and cancer. Founded in 2009 and based in Irvine, California, Bioniz has a pipeline that includes BNZ-1, a selective inhibitor of interleukin cytokines IL-2, IL-9, and IL-15, which are significant contributors to conditions such as HTLV-1 Associated Myelopathy and T-cell leukemias. The company is also developing IL-15 and IL-21 inhibitors, along with BNZ-3, an early-stage asset targeting IL-4, IL-9, and IL-21 cytokines. Bioniz Therapeutics aims to complete proof of concept and preclinical studies for its lead technologies while seeking partnerships for clinical trials and commercialization, reflecting its commitment to enhancing global public health through novel therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.